Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine

Fig. 2

PREEMPT 56-week data showed continued improvement in headache days with onabotulinumtoxinA. Source: [31]. This is a pooled analysis of PREEMPT 1 and 2: the double-blind phase included 688 subjects in the onabotulinumtoxinA group and 696 in the placebo group. Headache days at baseline: 19.9 onabotulinumtoxinA group vs 19.8 placebo group, p = 0.498. PREEMPT = Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us